-
Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study. Rheumatol Ther. 2023 Dec; 10(6):1741-1752.
Fineman MS, McAlindon TE, Lattermann C, Swearingen CJ, Kennedy S, Lopez VA, Simsek I, Tambiah JRS, Yazici Y. PMID: 37902943; PMCID: PMC10654271.
View in:
PubMed Mentions:
-
First-in-human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations. Diabetes Obes Metab. 2023 09; 25(9):2447-2456.
Fineman MS, Bryant CLN, Colbert K, Jozefiak TH, Petersen JS, Horowitz M, Vora J, Rayner CK, Wabnitz P, Nimgaonkar A. PMID: 37380614.
View in:
PubMed Mentions: Fields:
Translation:
HumansCTClinical Trials
-
Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes. PLoS One. 2018; 13(9):e0203946.
Henry RR, Frias JP, Walsh B, Skare S, Hemming J, Burns C, Bicsak TA, Baron A, Fineman M. PMID: 30252913; PMCID: PMC6155522.
View in:
PubMed Mentions:
10 Fields:
Translation:
Humans
-
Metformin-associated lactic acidosis: Moving towards a new paradigm? Diabetes Obes Metab. 2017 11; 19(11):1499-1501.
Bicsak TA, Walsh B, Fineman M. PMID: 28474371; PMCID: PMC5655765.
View in:
PubMed Mentions:
3 Fields:
Translation:
Humans
-
Spinal Disinhibition in Experimental and Clinical Painful Diabetic Neuropathy. Diabetes. 2017 05; 66(5):1380-1390.
Marshall AG, Lee-Kubli C, Azmi S, Zhang M, Ferdousi M, Mixcoatl-Zecuatl T, Petropoulos IN, Ponirakis G, Fineman MS, Fadavi H, Frizzi K, Tavakoli M, Jeziorska M, Jolivalt CG, Boulton AJM, Efron N, Calcutt NA, Malik RA. PMID: 28202580; PMCID: PMC5399611.
View in:
PubMed Mentions:
32 Fields:
Translation:
HumansAnimals
-
Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia. 2016 08; 59(8):1645-54.
DeFronzo RA, Buse JB, Kim T, Burns C, Skare S, Baron A, Fineman M. PMID: 27216492; PMCID: PMC4930485.
View in:
PubMed Mentions:
37 Fields:
Translation:
Humans
-
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care. 2016 Feb; 39(2):198-205.
Buse JB, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, Baron A, Fineman M. PMID: 26285584.
View in:
PubMed Mentions:
124 Fields:
Translation:
HumansCTClinical Trials
-
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013 Jan 12; 381(9861):117-24.
Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, Hoogwerf BJ, Gao A, Boardman MK, Fineman M, Porter L, Schernthaner G. PMID: 23141817.
View in:
PubMed Mentions:
188 Fields:
Translation:
Humans
-
Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012 Jun; 14(6):546-54.
Fineman MS, Mace KF, Diamant M, Darsow T, Cirincione BB, Booker Porter TK, Kinninger LA, Trautmann ME. PMID: 22236356.
View in:
PubMed Mentions:
60 Fields:
Translation:
Humans
-
Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet. 2011 Jan; 50(1):65-74.
Fineman M, Flanagan S, Taylor K, Aisporna M, Shen LZ, Mace KF, Walsh B, Diamant M, Cirincione B, Kothare P, Li WI, MacConell L. PMID: 21142268.
View in:
PubMed Mentions:
54 Fields:
Translation:
Humans
-
Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. Clin Ther. 2009 Apr; 31(4):806-15.
Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M. PMID: 19446153.
View in:
PubMed Mentions:
15 Fields:
Translation:
Humans
-
Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol. 2008 Dec; 48(12):1389-99.
Kothare PA, Linnebjerg H, Isaka Y, Uenaka K, Yamamura A, Yeo KP, de la Peña A, Teng CH, Mace K, Fineman M, Shigeta H, Sakata Y, Irie S. PMID: 19047364.
View in:
PubMed Mentions:
26 Fields:
Translation:
Humans
-
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008 Nov 29; 151(1-3):123-9.
Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, Wilding I, Nauck M, Horowitz M. PMID: 18675854.
View in:
PubMed Mentions:
87 Fields:
Translation:
Humans
-
The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther. 2007 Aug; 9(4):317-26.
Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M. PMID: 17705687.
View in:
PubMed Mentions:
15 Fields:
Translation:
HumansCTClinical Trials
-
Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes. J Clin Pharmacol. 2007 Jul; 47(7):798-805.
Kellmeyer TA, Kesty NC, Wang Y, Frias JP, Fineman MS. PMID: 17463219.
View in:
PubMed Mentions:
4 Fields:
Translation:
Humans
-
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007 Jun; 30(6):1487-93.
Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K. PMID: 17353504.
View in:
PubMed Mentions:
122 Fields:
Translation:
HumansCTClinical Trials
-
Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005 Nov; 90(11):5991-7.
Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MA. PMID: 16144950.
View in:
PubMed Mentions:
99 Fields:
Translation:
Humans
-
Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther. 2005 Jun; 7(3):467-77.
Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D. PMID: 15929678.
View in:
PubMed Mentions:
23 Fields:
Translation:
HumansCTClinical Trials
-
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005 May; 28(5):1092-100.
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. PMID: 15855572.
View in:
PubMed Mentions:
392 Fields:
Translation:
HumansCTClinical Trials
-
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005 May; 28(5):1083-91.
Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. PMID: 15855571.
View in:
PubMed Mentions:
304 Fields:
Translation:
HumansCTClinical Trials
-
Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol. 2005 May; 45(5):570-7.
Blase E, Taylor K, Gao HY, Wintle M, Fineman M. PMID: 15831781.
View in:
PubMed Mentions:
21 Fields:
Translation:
HumansCTClinical Trials
-
Properties of pramlintide and insulin upon mixing. Am J Health Syst Pharm. 2005 Apr 15; 62(8):816-22.
Weyer C, Fineman MS, Strobel S, Shen L, Data J, Kolterman OG, Sylvestri MF. PMID: 15821274.
View in:
PubMed Mentions:
10 Fields:
Translation:
HumansCTClinical Trials
-
A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther. 2005 Feb; 27(2):210-5.
Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, Fineman M. PMID: 15811484.
View in:
PubMed Mentions:
28 Fields:
Translation:
HumansCTClinical Trials
-
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005 Jan 15; 62(2):173-81.
Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. PMID: 15700891.
View in:
PubMed Mentions:
110 Fields:
Translation:
HumansCTClinical Trials
-
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004 Nov; 27(11):2628-35.
Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, Exenatide-113 Clinical Study Group. PMID: 15504997.
View in:
PubMed Mentions:
323 Fields:
Translation:
HumansCTClinical Trials
-
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes. 2004 Sep; 53(9):2397-403.
Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O. PMID: 15331551.
View in:
PubMed Mentions:
58 Fields:
Translation:
HumansCTClinical Trials
-
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev. 2004 Sep-Oct; 20(5):411-7.
Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. PMID: 15343588.
View in:
PubMed Mentions:
46 Fields:
Translation:
HumansCTClinical Trials
-
Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004 Apr; 12(4):661-8.
Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C. PMID: 15090634.
View in:
PubMed Mentions:
42 Fields:
Translation:
HumansCTClinical Trials
-
Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev. 2004 Jan-Feb; 20(1):55-60.
Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C. PMID: 14737746.
View in:
PubMed Mentions:
14 Fields:
Translation:
HumansCTClinical Trials
-
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003 Aug; 26(8):2370-7.
Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD. PMID: 12882864.
View in:
PubMed Mentions:
65 Fields:
Translation:
HumansCTClinical Trials
-
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003 Jul; 88(7):3082-9.
Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. PMID: 12843147.
View in:
PubMed Mentions:
140 Fields:
Translation:
HumansCTClinical Trials
-
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003 Mar; 26(3):784-90.
Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG. PMID: 12610038.
View in:
PubMed Mentions:
78 Fields:
Translation:
HumansCTClinical Trials
-
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002 Apr; 25(4):724-30.
Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG. PMID: 11919132.
View in:
PubMed Mentions:
66 Fields:
Translation:
HumansCTClinical Trials
-
Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther. 2002; 4(1):51-61.
Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG. PMID: 12017421.
View in:
PubMed Mentions:
33 Fields:
Translation:
HumansCTClinical Trials